hydroxychloroquine has been researched along with Obesity in 23 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is a common disease modifying therapy for the treatment of rheumatoid arthritis (RA)." | 6.77 | Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. ( Garg, R; Lu, B; Massarotti, EM; Mercer, E; Rekedal, L; Solomon, DH, 2012) |
| "Hydroxychloroquine (HCQ) has been demonstrated to reduce the risk to develop diabetes mellitus (DM)." | 5.43 | Favorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokines. ( Abdel-Hamid, AAM; Firgany, AEL, 2016) |
| "The increasing prevalence of obesity over the past 60 years implies the need to reassess the risk of hydroxychloroquine retinopathy (HR) in obese women using the American Academy of Ophthalmology (AAO) 2016 guidelines." | 3.91 | The 2016 American Academy of Ophthalmology Hydroxychloroquine Dosing Guidelines For Short, Obese Patients. ( Browning, DJ; Easterbrook, M; Lee, C, 2019) |
| " Subcutaneous administration of methotrexate was more effective than the oral administration at the same dosage in patients suffering from active rheumatoid arthritis." | 3.74 | [What's new in internal medicine?]. ( Francès, C, 2008) |
| "Hydroxychloroquine (HCQ) is a common disease modifying therapy for the treatment of rheumatoid arthritis (RA)." | 2.77 | Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. ( Garg, R; Lu, B; Massarotti, EM; Mercer, E; Rekedal, L; Solomon, DH, 2012) |
| "Rheumatic diseases were IA (60%) and CTD (40%)." | 1.56 | Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. ( Alvaro-Gracia, JM; Blanco, R; Carmona, L; Castrejón, I; Fernández Fernández, D; Fernandez-Nebro, A; Galindo, M; Gonzalez-Gay, MA; Lledó, A; Manrique-Arija, S; Martinez-Lopez, D; Mena Vázquez, N; Mera-Varela, A; Pablos, JL; Retuerto, M, 2020) |
| "It may cause severe viral pneumonia with Acute Respiratory Distress Syndrome requiring critical care." | 1.56 | Very severe COVID-19 in the critically ill in Tunisia. ( Boussarsar, M; Ennouri, E; Jerbi, S; Mahmoud, J; Meddeb, K; Nachi, R; Saida, IB; Thabet, N, 2020) |
| "Hydroxychloroquine (HCQ) has been demonstrated to reduce the risk to develop diabetes mellitus (DM)." | 1.43 | Favorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokines. ( Abdel-Hamid, AAM; Firgany, AEL, 2016) |
| "In 22 SLE patients with chronic renal insufficiency (median serum creatinine clearance 52 ml/minute [range 23-58 ml/minute]) who received 400 mg/day HCQ, the median blood HCQ concentration was significantly higher than that in the 509 patients from the PLUS study (1,338 ng/ml [range 504-2,229 ng/ml] versus 917 ng/ml [range 208-3316 ng/ml]) (P < 0." | 1.42 | Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. ( Ackermann, F; Amoura, Z; Asli, B; Aumaître, O; Blanchet, B; Cacoub, P; Cohen-Bittan, J; Costedoat-Chalumeau, N; Desmurs-Clavel, H; Fain, O; Francès, C; Galicier, L; Hulot, JS; Jallouli, M; Kahn, JE; Le Guern, V; Le Thi Huong, D; Leroux, G; Limal, N; Lioté, F; Mariette, X; Papo, T; Perard, L; Piette, JC; Pourrat, J; Sacré, K; Sailler, L; Sellam, J; Smail, A; Stirnemann, J; Zahr, N, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.70) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 14 (60.87) | 2.80 |
| Authors | Studies |
|---|---|
| Ferron, PJ | 1 |
| Le Daré, B | 1 |
| Bronsard, J | 1 |
| Steichen, C | 1 |
| Babina, E | 1 |
| Pelletier, R | 1 |
| Hauet, T | 1 |
| Morel, I | 1 |
| Tarte, K | 1 |
| Reizine, F | 1 |
| Clément, B | 1 |
| Fromenty, B | 1 |
| Gicquel, T | 1 |
| Browning, DJ | 1 |
| Easterbrook, M | 2 |
| Lee, C | 1 |
| Marmor, MF | 1 |
| Caldas, R | 1 |
| Guimarães, MJ | 1 |
| Rodrigues, AP | 1 |
| Araújo, C | 1 |
| Lipworth, B | 1 |
| Chan, R | 1 |
| Lipworth, S | 1 |
| RuiWen Kuo, C | 1 |
| Defoort-Dhellemmes, S | 1 |
| Chee, YJ | 1 |
| Tan, SK | 1 |
| Yeoh, E | 1 |
| Deane, KD | 1 |
| Holers, VM | 1 |
| Azmy, V | 1 |
| Benson, J | 1 |
| Love, K | 1 |
| Steele, R | 1 |
| Wang, Y | 1 |
| Foo, R | 1 |
| Thum, T | 1 |
| Choi, NH | 1 |
| Silver, ES | 1 |
| Fremed, M | 1 |
| Liberman, L | 1 |
| Pablos, JL | 1 |
| Galindo, M | 1 |
| Carmona, L | 1 |
| Lledó, A | 1 |
| Retuerto, M | 1 |
| Blanco, R | 1 |
| Gonzalez-Gay, MA | 1 |
| Martinez-Lopez, D | 1 |
| Castrejón, I | 1 |
| Alvaro-Gracia, JM | 1 |
| Fernández Fernández, D | 1 |
| Mera-Varela, A | 1 |
| Manrique-Arija, S | 1 |
| Mena Vázquez, N | 1 |
| Fernandez-Nebro, A | 1 |
| Sobol, I | 1 |
| Yuzefpolskaya, M | 1 |
| Roth, Z | 1 |
| Colombo, PC | 1 |
| Horn, E | 1 |
| Takeda, K | 1 |
| Sayer, G | 1 |
| Uriel, N | 1 |
| Naka, Y | 1 |
| Saida, IB | 1 |
| Ennouri, E | 1 |
| Nachi, R | 1 |
| Meddeb, K | 1 |
| Mahmoud, J | 1 |
| Thabet, N | 1 |
| Jerbi, S | 1 |
| Boussarsar, M | 1 |
| Riou, M | 1 |
| Marcot, C | 1 |
| Canuet, M | 1 |
| Renaud-Picard, B | 1 |
| Chatron, E | 1 |
| Porzio, M | 1 |
| Dégot, T | 1 |
| Hirschi, S | 1 |
| Metz-Favre, C | 1 |
| Kassegne, L | 1 |
| Ederle, C | 1 |
| Khayath, N | 1 |
| Labani, A | 1 |
| Leyendecker, P | 1 |
| De Blay, F | 1 |
| Kessler, R | 1 |
| Lee, KH | 1 |
| Kim, JS | 1 |
| Hong, SH | 1 |
| Seong, D | 1 |
| Choi, YR | 1 |
| Ahn, YT | 1 |
| Kim, KS | 1 |
| Kim, SE | 1 |
| Lee, S | 1 |
| Sim, W | 1 |
| Kim, D | 1 |
| Jun, B | 1 |
| Yang, JW | 1 |
| Yon, DK | 1 |
| Lee, SW | 1 |
| Kim, MS | 1 |
| Dragioti, E | 1 |
| Li, H | 1 |
| Jacob, L | 1 |
| Koyanagi, A | 1 |
| Abou Ghayda, R | 1 |
| Shin, JI | 1 |
| Smith, L | 1 |
| Ruíz-Quiñonez, JA | 1 |
| Guzmán-Priego, CG | 1 |
| Nolasco-Rosales, GA | 1 |
| Tovilla-Zarate, CA | 1 |
| Flores-Barrientos, OI | 1 |
| Narváez-Osorio, V | 1 |
| Baeza-Flores, GDC | 1 |
| Gonzalez-Castro, TB | 1 |
| López-Brito, CR | 1 |
| Denis-García, CA | 1 |
| Pérez-García, A | 1 |
| Juárez-Rojop, IE | 1 |
| Jallouli, M | 1 |
| Galicier, L | 1 |
| Zahr, N | 1 |
| Aumaître, O | 1 |
| Francès, C | 2 |
| Le Guern, V | 1 |
| Lioté, F | 1 |
| Smail, A | 1 |
| Limal, N | 1 |
| Perard, L | 1 |
| Desmurs-Clavel, H | 1 |
| Le Thi Huong, D | 1 |
| Asli, B | 1 |
| Kahn, JE | 1 |
| Pourrat, J | 1 |
| Sailler, L | 1 |
| Ackermann, F | 1 |
| Papo, T | 1 |
| Sacré, K | 1 |
| Fain, O | 1 |
| Stirnemann, J | 1 |
| Cacoub, P | 1 |
| Leroux, G | 1 |
| Cohen-Bittan, J | 1 |
| Sellam, J | 1 |
| Mariette, X | 1 |
| Blanchet, B | 1 |
| Hulot, JS | 1 |
| Amoura, Z | 1 |
| Piette, JC | 1 |
| Costedoat-Chalumeau, N | 1 |
| Wasko, MC | 1 |
| McClure, CK | 1 |
| Kelsey, SF | 1 |
| Huber, K | 1 |
| Orchard, T | 1 |
| Toledo, FG | 1 |
| Abdel-Hamid, AAM | 1 |
| Firgany, AEL | 1 |
| Mercer, E | 1 |
| Rekedal, L | 1 |
| Garg, R | 1 |
| Lu, B | 1 |
| Massarotti, EM | 1 |
| Solomon, DH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fecal Microbial Transplantation for Rheumatoid Arthritis Trial[NCT05790356] | 30 participants (Anticipated) | Interventional | 2023-07-01 | Not yet recruiting | |||
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes[NCT01326533] | Phase 4 | 32 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.[NCT02874287] | Phase 4 | 35 participants (Actual) | Interventional | 2017-10-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
Change from baseline in the disposition index (DI) (NCT01326533)
Timeframe: 13 weeks after baseline measurement
| Intervention | arbitrary units (Mean) |
|---|---|
| Hydroxychloroquine | 352 |
| Placebo | -218 |
Change from baseline in the insulin sensitivity index (Si) (NCT01326533)
Timeframe: 13 weeks after baseline measurement
| Intervention | 10^-4/pmol*l/min (Mean) |
|---|---|
| Hydroxychloroquine | 0.08 |
| Placebo | -0.11 |
3 reviews available for hydroxychloroquine and Obesity
| Article | Year |
|---|---|
Dissecting the interaction between COVID-19 and diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID- | 2020 |
Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift.
Topics: Alcohol Drinking; Anti-Citrullinated Protein Antibodies; Antirheumatic Agents; Arthralgia; Arthritis | 2021 |
Risk factors of COVID-19 mortality: a systematic review of current literature and lessons from recent retracted articles.
Topics: Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Asian Peopl | 2020 |
2 trials available for hydroxychloroquine and Obesity
| Article | Year |
|---|---|
Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial.
Topics: Adult; Blood Glucose; Cytokines; Double-Blind Method; Female; Humans; Hydroxychloroquine; Insulin; I | 2015 |
Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals.
Topics: Antirheumatic Agents; Body Mass Index; Female; Humans; Hydroxychloroquine; Insulin Resistance; Longi | 2012 |
18 other studies available for hydroxychloroquine and Obesity
| Article | Year |
|---|---|
Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients.
Topics: Aged; Antiviral Agents; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Correlatio | 2021 |
The 2016 American Academy of Ophthalmology Hydroxychloroquine Dosing Guidelines For Short, Obese Patients.
Topics: Academies and Institutes; Adult; Aged; Antirheumatic Agents; Body Mass Index; Cross-Sectional Studie | 2019 |
The 2016 American Academy of Ophthalmology Recommendations for Hydroxychloroquine Dosing Give Accurate Advice for All Patients.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Obesity; Ophthalmology; Retinal Diseases; United S | 2019 |
Generalised papular variant of elastolytic giant cell granuloma.
Topics: Aged; Diabetes Complications; Granuloma Annulare; Granuloma, Giant Cell; Griseofulvin; Humans; Hydro | 2019 |
Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Age Factors; Angiotensin-Converting Enzyme Inhi | 2020 |
[Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?]
Topics: Antimalarials; Betacoronavirus; Bone Density Conservation Agents; Contraindications, Drug; Coronavir | 2020 |
Idiopathic nonhistaminergic acquired angioedema in a patient with coronavirus disease 2019.
Topics: Adenosine Monophosphate; Adult; Alanine; Ampicillin; Angioedema; Betacoronavirus; Coronavirus Infect | 2020 |
Using "old" medications to fight new COVID-19: Re-purposing with a purpose.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betaco | 2020 |
COVID-19 reveals Brugada pattern in an adolescent patient.
Topics: Antiviral Agents; Brugada Syndrome; C-Reactive Protein; Chest Pain; Consanguinity; Cough; COVID-19; | 2020 |
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Antiviral Agents; Arthritis, Psoriatic; Arthrit | 2020 |
Characteristics and Outcomes of Patients With a Left Ventricular Assist Device With Coronavirus Disease-19.
Topics: Adult; Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Diabetes Mellitus; F | 2020 |
Very severe COVID-19 in the critically ill in Tunisia.
Topics: Antiviral Agents; Betacoronavirus; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COV | 2020 |
Clinical characteristics of and outcomes for patients with COVID-19 and comorbid lung diseases primarily hospitalized in a conventional pulmonology unit: A retrospective study.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Ch | 2021 |
Features of patients that died for COVID-19 in a hospital in the south of Mexico: A observational cohort study.
Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 1; Female; Hos | 2021 |
Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Body Mass Index; Creatinine; Female; Humans; H | 2015 |
Favorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokines.
Topics: Adipokines; Animals; Diet, High-Fat; Endothelial Cells; Hydroxychloroquine; Insulin Resistance; Insu | 2016 |
[What's new in internal medicine?].
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Bacteriophages; Body Mass | 2008 |
Dosage of hydroxychloroquine should be based on ideal body weight: comment on the letter by Alarcón.
Topics: Adult; Antimalarials; Body Height; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; D | 2003 |